BRECCIA, Igina Maria
BRECCIA, Igina Maria
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
2019 Caocci, G.; Mulas, O.; Abruzzese, E.; Luciano, L.; Iurlo, A.; Attolico, I.; Castagnetti, F.; Galimberti, S.; Sgherza, N.; Bonifacio, M.; Annunziata, M.; Gozzini, A.; Orlandi, E. M.; Stagno, F.; Binotto, G.; Pregno, P.; Fozza, C.; Trawinska, M. M.; De Gregorio, F.; Cattaneo, D.; Albano, F.; Gugliotta, G.; Barate, C.; Scaffidi, L.; Elena, C.; Pirillo, F.; Scalzulli, E.; La Nasa, G.; Foa, R.; Breccia, M.
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia. is it time to introduce it in the clinical practice?
2020 Colafigli, G.; Scalzulli, E.; Di Prima, A.; Pepe, S.; Loglisci, M. G.; Diverio, D.; Martelli, M.; Foa, R.; Breccia, M.
Elderly patients with PH+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment
2005 Latagliata, R.; Breccia, M.; Carmosino, I.; Sarlo, C.; Montefusco, E.; Mancini, M.; Natalino, F.; Chistolini, A.; De Cuia, R.; Russo, E.; Morano, G. S.; Biondo, F.; Spadea, A.; Mandelli, F.; Alimena, G.
Genitorialità e suoi destini. Intervista a Vittorio Lingiardi sull'omogenitorialità
2014 Breccia, M.; Lingiardi, V.
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia
2019 Efficace, F.; Breccia, M.; Avvisati, G.; Cottone, F.; Intermesoli, T.; Borlenghi, E.; Carluccio, P.; Rodeghiero, Flavio; Fabbiano, F.; Luppi, M.; Romani, Cristina; Sborgia, M.; D'Ardia, S.; Nobile, F.; Cantore, N.; Crugnola, M.; Nadali, G.; Vignetti, M.; Amadori, S.; Lo Coco, F.
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
2019 Caocci, G.; Mulas, O.; Abruzzese, E.; Iurlo, A.; Annunziata, M.; Orlandi, E. M.; Galimberti, S.; Binotto, G.; Sgherza, N.; Luciano, L.; Martino, B.; Russo Rossi, A.; DI BONIFACIO, Marco; Fozza, C.; Trawinska, M. M.; Cattaneo, D.; Elena, C.; Barate, C.; De Gregorio, F.; Molica, M.; La Nasa, G.; Foa, R.; Breccia, M.
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia
2019 Breccia, M.; Foa, R.
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative
2019 Loscocco, G. G.; Mannelli, F.; Guglielmelli, P.; Paoli, C.; Marone, I.; Cucci, R.; Coltro, G.; Sordi, Bernardo; Albano, F.; Breccia, M.; DE STEFANO, Valeria; Finazzi, Giovanni; Iurlo, A.; Martino, B.; Palandri, F.; Passamonti, F.; Siragusa, S.; Mannelli, L.; Fantoni, D.; Fazi, P.; Amadori, S.; Vignetti, M.; Barbui, T.; Vannucchi, A. M.
Maintenance therapy in AML: the past, the present and the future
2019 Molica, M.; Breccia, M.; Foa, R.; Jabbour, E.; Kadia, T. M.
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab
2020 Di Prima, A.; Botticelli, A.; Scalzulli, E.; Colafigli, G.; Pepe, S.; Lisi, C.; Marchetti, P.; Martelli, M.; Foa, R.; Breccia, M.
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience
2020 Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M.
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study
2015 Efficace, F; Gaidano, G; Breccia, M; Voso, Mt; Cottone, F; Angelucci, E; Caocci, G; Stauder, R; Selleslag, D; Sprangers, M; Platzbecker, U; Ricco, A; Sanpaolo, G; Beyne-Rauzy, O; Buccisano, F; Palumbo, Ga; Bowen, D; Nguyen, K; Niscola, P; Vignetti, M; Mandelli, F.
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention
2019 Caocci, G.; Mulas, O.; Bonifacio, M.; Abruzzese, E.; Galimberti, S.; Orlandi, E. M.; Iurlo, A.; Annunziata, M.; Luciano, L.; Castagnetti, F.; Gozzini, A.; Stagno, F.; Binotto, G.; Pregno, P.; Albano, F.; Martino, B.; Fozza, C.; Scaffidi, L.; Trawinska, M. M.; Barate, C.; Elena, C.; Cattaneo, D.; Scalzulli, E.; La Nasa, G.; Foa, R.; Breccia, M.
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients
2020 Scalzulli, E.; Colafigli, G.; Latagliata, R.; Pepe, S.; Diverio, D.; Stocchi, F.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M.
The advantages and risks of ruxolitinib for the treatment of polycythemia vera
2020 Colafigli, G.; Scalzulli, E.; Pepe, S.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M.
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
2019 Molica, M; Breccia, M; Capria, S; Trisolini, S; Foa, R; Jabbour, E; Kadia, Tm.
Treatment-Free Remission in Chronic Myeloid Leukemia
2019 Molica, M; Naqvi, K; Cortes, Je; Paul, S; Kadia, Tm; Breccia, M; Kantarjian, H; Jabbour, Ej
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart | 2019 | Caocci, G.; Mulas, O.; Abruzzese, E.; Luciano, L.; Iurlo, A.; Attolico, I.; Castagnetti, F.; Galimberti, S.; Sgherza, N.; Bonifacio, M.; Annunziata, M.; Gozzini, A.; Orlandi, E. M.; Stagno, F.; Binotto, G.; Pregno, P.; Fozza, C.; Trawinska, M. M.; De Gregorio, F.; Cattaneo, D.; Albano, F.; Gugliotta, G.; Barate, C.; Scaffidi, L.; Elena, C.; Pirillo, F.; Scalzulli, E.; La Nasa, G.; Foa, R.; Breccia, M. | |
| Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia. is it time to introduce it in the clinical practice? | 2020 | Colafigli, G.; Scalzulli, E.; Di Prima, A.; Pepe, S.; Loglisci, M. G.; Diverio, D.; Martelli, M.; Foa, R.; Breccia, M. | |
| Elderly patients with PH+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment | 2005 | Latagliata, R.; Breccia, M.; Carmosino, I.; Sarlo, C.; Montefusco, E.; Mancini, M.; Natalino, F.; Chistolini, A.; De Cuia, R.; Russo, E.; Morano, G. S.; Biondo, F.; Spadea, A.; Mandelli, F.; Alimena, G. | |
| Genitorialità e suoi destini. Intervista a Vittorio Lingiardi sull'omogenitorialità | 2014 | Breccia, M.; Lingiardi, V. | |
| Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia | 2019 | Efficace, F.; Breccia, M.; Avvisati, G.; Cottone, F.; Intermesoli, T.; Borlenghi, E.; Carluccio, P.; Rodeghiero, Flavio; Fabbiano, F.; Luppi, M.; Romani, Cristina; Sborgia, M.; D'Ardia, S.; Nobile, F.; Cantore, N.; Crugnola, M.; Nadali, G.; Vignetti, M.; Amadori, S.; Lo Coco, F. | |
| Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice | 2019 | Caocci, G.; Mulas, O.; Abruzzese, E.; Iurlo, A.; Annunziata, M.; Orlandi, E. M.; Galimberti, S.; Binotto, G.; Sgherza, N.; Luciano, L.; Martino, B.; Russo Rossi, A.; DI BONIFACIO, Marco; Fozza, C.; Trawinska, M. M.; Cattaneo, D.; Elena, C.; Barate, C.; De Gregorio, F.; Molica, M.; La Nasa, G.; Foa, R.; Breccia, M. | |
| Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia | 2019 | Breccia, M.; Foa, R. | |
| Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative | 2019 | Loscocco, G. G.; Mannelli, F.; Guglielmelli, P.; Paoli, C.; Marone, I.; Cucci, R.; Coltro, G.; Sordi, Bernardo; Albano, F.; Breccia, M.; DE STEFANO, Valeria; Finazzi, Giovanni; Iurlo, A.; Martino, B.; Palandri, F.; Passamonti, F.; Siragusa, S.; Mannelli, L.; Fantoni, D.; Fazi, P.; Amadori, S.; Vignetti, M.; Barbui, T.; Vannucchi, A. M. | |
| Maintenance therapy in AML: the past, the present and the future | 2019 | Molica, M.; Breccia, M.; Foa, R.; Jabbour, E.; Kadia, T. M. | |
| Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab | 2020 | Di Prima, A.; Botticelli, A.; Scalzulli, E.; Colafigli, G.; Pepe, S.; Lisi, C.; Marchetti, P.; Martelli, M.; Foa, R.; Breccia, M. | |
| Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience | 2020 | Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M. | |
| Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study | 2015 | Efficace, F; Gaidano, G; Breccia, M; Voso, Mt; Cottone, F; Angelucci, E; Caocci, G; Stauder, R; Selleslag, D; Sprangers, M; Platzbecker, U; Ricco, A; Sanpaolo, G; Beyne-Rauzy, O; Buccisano, F; Palumbo, Ga; Bowen, D; Nguyen, K; Niscola, P; Vignetti, M; Mandelli, F. | |
| Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention | 2019 | Caocci, G.; Mulas, O.; Bonifacio, M.; Abruzzese, E.; Galimberti, S.; Orlandi, E. M.; Iurlo, A.; Annunziata, M.; Luciano, L.; Castagnetti, F.; Gozzini, A.; Stagno, F.; Binotto, G.; Pregno, P.; Albano, F.; Martino, B.; Fozza, C.; Scaffidi, L.; Trawinska, M. M.; Barate, C.; Elena, C.; Cattaneo, D.; Scalzulli, E.; La Nasa, G.; Foa, R.; Breccia, M. | |
| Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients | 2020 | Scalzulli, E.; Colafigli, G.; Latagliata, R.; Pepe, S.; Diverio, D.; Stocchi, F.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M. | |
| The advantages and risks of ruxolitinib for the treatment of polycythemia vera | 2020 | Colafigli, G.; Scalzulli, E.; Pepe, S.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M. | |
| The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. | 2019 | Molica, M; Breccia, M; Capria, S; Trisolini, S; Foa, R; Jabbour, E; Kadia, Tm. | |
| Treatment-Free Remission in Chronic Myeloid Leukemia | 2019 | Molica, M; Naqvi, K; Cortes, Je; Paul, S; Kadia, Tm; Breccia, M; Kantarjian, H; Jabbour, Ej |